ETF Holdings Breakdown of GPCR

GPCR institutional holdings

The adjusted close for GPCR on 2025-11-12 was 35.92

The following institutional investment holdings of GPCR have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	38,334	USD 1,376,957	35.92
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	38,334	USD 1,376,957	35.92
Total =		76,668	USD 2,753,914

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with GPCR

Structure Therapeutics (NASDAQ:GPCR) Raised to “Strong-Buy” at Lifesci Capital

Lifesci Capital upgraded shares of Structure Therapeutics (NASDAQ:GPCR – Free Report) to a strong-buy rating in a research report report published on Monday morning,Zacks.com reports. A number of other equities research analysts have also recently issued reports on GPCR. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Structure […] - 2025-09-11 02:43:02

Analysts Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $75.71

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report) has received a consensus rating of “Buy” from the eight analysts that are currently covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the […] - 2025-08-25 03:00:58

Alps Advisors Inc. Sells 3,220 Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

Alps Advisors Inc. trimmed its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) by 7.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 43,080 shares of the company’s stock after selling 3,220 shares during the quarter. Alps Advisors Inc.’s holdings […] - 2025-07-15 06:24:40

Structure Therapeutics Enters Oversold Territory (GPCR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me - 2025-07-07 12:55:24

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of “Buy” from Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report) has been given a consensus recommendation of “Buy” by the seven brokerages that are currently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the […] - 2025-07-03 02:56:55

Structure Therapeutics (NASDAQ:GPCR) Receives Overweight Rating from Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued on Monday,Benzinga reports. They currently have a $65.00 price target on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 190.44% from the stock’s current price. Several […] - 2025-06-25 02:36:50

JMP Securities Reiterates Market Outperform Rating for Structure Therapeutics (NASDAQ:GPCR)

Structure Therapeutics (NASDAQ:GPCR – Get Free Report)‘s stock had its “market outperform” rating reissued by equities research analysts at JMP Securities in a research note issued to investors on Monday,Benzinga reports. They presently have a $89.00 target price on the stock. JMP Securities’ target price would suggest a potential upside of 297.68% from the stock’s […] - 2025-06-25 02:36:49

Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Price Target at $76.50

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the […] - 2025-06-11 02:54:42

Bank of America Corp DE Has $1.47 Million Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Bank of America Corp DE reduced its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 36.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 54,185 shares of the company’s stock after selling 31,021 shares during the quarter. […] - 2025-06-05 04:38:48

Universal Beteiligungs und Servicegesellschaft mbH Makes New $3.09 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 113,992 shares of the company’s stock, valued at approximately $3,091,000. Universal Beteiligungs und Servicegesellschaft mbH owned […] - 2025-06-03 05:10:53

Structure Therapeutics (NASDAQ:GPCR) Price Target Lowered to $75.00 at HC Wainwright

Structure Therapeutics (NASDAQ:GPCR – Free Report) had its price target cut by HC Wainwright from $80.00 to $75.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the stock. A number of other brokerages also recently issued reports on GPCR. William Blair initiated coverage on shares of Structure Therapeutics […] - 2025-05-13 02:42:58

Tower Research Capital LLC TRC Buys 3,549 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Tower Research Capital LLC TRC boosted its stake in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 673.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,076 shares of the company’s stock after purchasing an additional 3,549 shares during the […] - 2025-05-09 05:54:58

Envestnet Asset Management Inc. Acquires 843 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Envestnet Asset Management Inc. grew its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 12.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 7,403 shares of the company’s stock after purchasing an additional 843 shares during the period. Envestnet Asset Management Inc.’s holdings in Structure Therapeutics were worth $201,000 […] - 2025-05-09 04:18:46

Barclays PLC Boosts Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

Barclays PLC lifted its position in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 42.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 115,671 shares of the company’s stock after purchasing an additional 34,533 shares during the quarter. Barclays PLC’s […] - 2025-04-30 05:12:48

Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have earned an average rating of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on […] - 2025-04-22 02:34:58

Bank of Montreal Can Purchases 3,671 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Bank of Montreal Can lifted its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 7.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,173 shares of the company’s stock after buying an additional 3,671 shares during the quarter. […] - 2025-04-18 05:08:54

Alliancebernstein L.P. Sells 16,372 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Alliancebernstein L.P. trimmed its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 10.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 142,825 shares of the company’s stock after selling 16,372 shares during the quarter. Alliancebernstein L.P.’s holdings in […] - 2025-04-15 04:52:54

American Century Companies Inc. Purchases 67,325 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

American Century Companies Inc. increased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 12.3% in the 4th quarter, HoldingsChannel reports. The fund owned 612,616 shares of the company’s stock after acquiring an additional 67,325 shares during the period. American Century Companies Inc.’s holdings in Structure Therapeutics were worth $16,614,000 as […] - 2025-04-01 05:04:51

Natixis Advisors LLC Reduces Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Natixis Advisors LLC decreased its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 45.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,459 shares of the company’s stock after selling 12,216 shares during the quarter. Natixis Advisors LLC’s […] - 2025-03-28 06:04:49

Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Consensus Target Price from Brokerages

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in […] - 2025-03-28 03:34:46

Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by M&T Bank Corp

M&T Bank Corp raised its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 100.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,110 shares of the company’s stock after purchasing an additional 9,055 shares during the period. […] - 2025-03-14 06:54:57

Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Consensus PT from Brokerages

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned a consensus rating of “Buy” from the eight research firms that are covering the company, MarketBeat reports. Eight equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on […] - 2025-03-05 04:58:44

abrdn plc Has $4.65 Million Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

abrdn plc lessened its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 21.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 171,388 shares of the company’s stock after selling 45,695 shares during the quarter. abrdn plc’s holdings in […] - 2025-02-10 16:42:59

Spire Wealth Management Makes New $243,000 Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Spire Wealth Management bought a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 8,949 shares of the company’s stock, valued at approximately $243,000. Several other hedge funds and other institutional investors also recently made changes to their positions in GPCR. Point72 Asset Management […] - 2025-02-07 07:04:12

Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned an average rating of “Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have covered the stock in the […] - 2025-02-06 04:06:45

Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 10,750,000 shares, a growth of 5.8% from the December 31st total of 10,160,000 shares. Approximately 19.8% of the company’s shares are sold short. […] - 2025-02-03 04:12:44

Back to Listing

Disclaimer